¼¼°èÀÇ Àü¸³¼± °Ç°­ ½ÃÀå
Prostate Health
»óǰÄÚµå : 1731877
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 463 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,106,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,320,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Àü¸³¼± °Ç°­ ½ÃÀåÀº 2030³â±îÁö 512¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 338¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Àü¸³¼± °Ç°­ ½ÃÀåÀº 2024-2030³â¿¡ CAGR 7.2%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 512¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ Àü¸³¼±¿° ÁúȯÀº CAGR 5.7%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 274¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾ç¼º Àü¸³¼± ºñ´ëÁõÇü ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 9.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 92¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 11.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Àü¸³¼± °Ç°­ ½ÃÀåÀº 2024³â¿¡ 92¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 106¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 11.0%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.7%¿Í 6.8%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ "Àü¸³¼± °Ç°­" ½ÃÀå - ¿Ö ÇÁ·Î¾×Ƽºê Äɾ ¼¼°èÀÇ ¸ÇÁî Çコ¿¡ À־ Çʼö°¡ µÇ°í Àִ°¡?

°í·ÉÈ­·Î ÀÎÇØ Àü¸³¼± °Ç°­ÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ´Ù?

Àü¸³¼± °Ç°­Àº ³²¼º Àα¸ÀÇ ±Þ¼ÓÇÑ °í·ÉÈ­¿Í ºñ´¢±â Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÇ ÇÙ½É °ü½É»ç°¡ µÇ°í ÀÖ½À´Ï´Ù. Àü¸³¼±ºñ´ëÁõ(BPH), Àü¸³¼±¿°, Àü¸³¼±¾Ï°ú °°Àº Àü¸³¼± °ü·Ã ÁúȯÀº 50¼¼ ÀÌ»ó ³²¼ºµé »çÀÌ¿¡¼­ Á¡Á¡ ´õ ¸¹ÀÌ ¹ß»ýÇϰí ÀÖÀ¸¸ç, ¿¹¹æ, Áø´Ü ¹× Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °øÁߺ¸°Ç Ä·ÆäÀΰú °ËÁø ÇÁ·ÎÅäÄÝÀÇ °­È­´Â Á¶±â ¹ß°ßÀ¸·Î À̾îÁ® ¿¹Èĸ¦ °³¼±Çϰí Ä¡·á ±â°£À» ¿¬ÀåÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºñ¸¸, Èí¿¬, Á½ĻýȰ µî »ýȰ½À°ü °ü·Ã À§Çè¿äÀÎÀÌ ÀþÀº ¿¬·ÉÃþ¿¡¼­µµ Àü¸³¼± ÁúȯÀÇ ¹ßº´·üÀ» ¾ÇÈ­½Ã۰í ÀÖÀ¸¸ç, PSA °Ë»ç, MRI, °æÁ÷Àå ÃÊÀ½ÆÄ °Ë»ç µî Áø´Ü ÅøÀÇ ¹ß´Þ·Î Àü¸³¼± °Ç°­ ¸ð´ÏÅ͸µÀÌ ´õ¿í °£ÆíÇϰí Á¤È®ÇÏ°Ô ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ƯÈ÷ ºÏ¹Ì, À¯·´, ¾Æ½Ã¾Æ ÀϺΠÁö¿ª¿¡¼­´Â Á¤ºÎ¿Í ÀÇ·á ±â°üÀÌ ³²¼ºÀÇ Á¤±â °Ç°­°ËÁø¿¡ Àü¸³¼± °ËÁøÀ» Æ÷ÇÔ½ÃŰ¸é¼­ ÀÓ»óÀû °³ÀÔ¿¡ ´ëÇÑ Àνİú ¼ö¿ä°¡ ´õ¿í ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

Áø´Ü°ú Ä¡·áÀÇ Çõ½ÅÀÌ ÀÓ»ó °á°ú¸¦ Çâ»ó½Ã۰í Àִ°¡?

Àü¸³¼± °Ç°­ ½ÃÀåÀº Áø´Ü ¹× Ä¡·á ±â¼úÀÇ ¹ßÀüÀ¸·Î Å« ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. ·¹ÀÌÀú Ä¡·á, TURP(°æ¿äµµÀû Àü¸³¼± ÀýÁ¦¼ú), ÃֽŠ·Îº¿ º¸Á¶ ¼ö¼ú°ú °°Àº ÃÖ¼Òħ½À ¼ö¼ú ±â¼úÀº ȸº¹ ½Ã°£À» ´ÜÃàÇϰí ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¾à¸®ÇÐÀûÀÎ Çõ½Åµµ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. »õ·Î¿î ¼¼´ëÀÇ ¾ËÆÄ Â÷´ÜÁ¦, 5¾ËÆÄ ȯ¿øÈ¿¼Ò ¾ïÁ¦Á¦, È£¸£¸ó ¿ä¹ýÀº ºÎÀÛ¿ëÀ» ÁÙÀ̸鼭 º¸´Ù È¿°úÀûÀÎ Áõ»ó °ü¸®¸¦ Á¦°øÇÕ´Ï´Ù. ¿µ»ó Áø´Ü¿¡¼­´Â ´ÙÁß ÆÄ¶ó¹ÌÅÍ MRI¿Í ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý °Ë»ç¸¦ ÅëÇØ ¾ç¼º Áúȯ°ú ¾Ç¼º Á¾¾çÀ» ´õ ºü¸£°í Á¤È®ÇÏ°Ô ±¸º°ÇÒ ¼ö ÀÖ°Ô µÇ¾î Á¤È®µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸é¿ª¿ä¹ý ¹× ¹æ»ç¼º ÀǾàǰ ¿¬±¸´Â ÁøÇ༺ Àü¸³¼±¾Ï Ä¡·á¿¡ À¯¸ÁÇÑ Ä¡·á¹ýÀ¸·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù. ¿ø°Ý ºñ´¢±â°ú Ç÷§Æû ¹× ¸ð¹ÙÀÏ °Ç°­ ¾Û°ú °°Àº µðÁöÅÐ °Ç°­ ÅøÀº ȯÀÚÀÇ ¼øÀÀµµ, Áõ»ó ÃßÀû ¹× °¡»ó »ó´ãÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. Áø´Ü°ú Ä¡·á°¡ ´õ¿í ÅëÇյʿ¡ µû¶ó ÀüüÀûÀÎ Ä¡·á °æ·Î°¡ µîÀåÇϰí ÀÓ»ó ¿öÅ©Ç÷οì¿Í ȯÀÚ °á°ú°¡ °³¼±µÇ°í ÀÖ½À´Ï´Ù.

³²¼ºÀÇ °Ç°­ Àǽİú ¼Òºñ ÇൿÀÌ ¼ö¿ä¸¦ °ßÀÎ?

³²¼º °Ç°­¿¡ ´ëÇÑ »çȸÀû ÀνÄÀÇ º¯È­´Â Àü¸³¼± °Ç°­ÀÇ »óȲÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. °ú°Å¿¡´Â ³«Àΰú °æ½Ã ¶§¹®¿¡ °ú¼Ò Áø´ÜµÇ¾ú´ø Àü¸³¼± ÁúȯÀº À¯¸íÀÎ, ÀÇÇаè, µðÁöÅÐ ÀÎÇ÷ç¾ð¼­µéÀÇ ¿ËÈ£·Î ÀÎÇØ ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ÀþÀº ¼¼´ë´Â ¿¹¹æÀÇÇп¡ Àû±ØÀûÀ̸ç, Á¤±â °ËÁø ¹× À¯ÀüÀÚ °Ë»ç¿¡ Âü¿©Çϰí ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ Á÷Á¢ ÆÇ¸Å °Ç°­ Ç÷§Æû°ú °¡Á¤¿ë °Ë»ç ŰƮ´Â ³²¼º¿¡°Ô ÇコÄɾîÀÇ ÀÚÀ²¼ºÀ» ºÎ¿©Çϰí, ¾à±¹ ¹× 1Â÷ Áø·á¼Ò´Â Àü¸³¼± Àü¹® ¼­ºñ½º¸¦ ´õ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ¼º °Ç°­°ú »îÀÇ Áú¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ BPH³ª ¹ß±âºÎÀü µî Àü¸³¼± °Ç°­°ú »óÈ£ ¿¬°üµÈ ÁúȯÀ» Á¶±â¿¡ Ä¡·á¹ÞÀ¸·Á´Â ȯÀÚµéÀÌ ´Ã°í ÀÖ½À´Ï´Ù. ³²¼ºµéÀº ¿ä½Ç±ÝÀ̳ª ¾Ï°ú °°Àº Àü¸³¼± ÁúȯÀÇ Àå±âÀûÀÎ ¿µÇâ¿¡ ´ëÇÑ Áö½ÄÀÌ ³ô¾ÆÁö¸é¼­ ÇÁ¸®¹Ì¾ö Áø´Ü, ¼¼ÄÁµå ¿ÀÇǴϾð, Áö¼ÓÀûÀÎ Ä¡·á ¿ä¹ý¿¡ ´ëÇÑ ÅõÀÚ¿¡ ´ëÇÑ ÀÇÁö°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÇൿÀÇ º¯È­·Î ÀÎÇØ ½ÃÀåÀº ¼Ò±ØÀû Ä¡·á¿¡¼­ º¸´Ù ¿¹¹æÀûÀÌ°í °³º°È­µÈ ȯÀÚ Áß½ÉÀûÀÎ ¸ðµ¨·Î Á¡Â÷ ÀüȯµÇ°í ÀÖ½À´Ï´Ù.

Àü¸³¼± °Ç°­ ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù.

Àü¸³¼± °Ç°­ ½ÃÀåÀÇ ¼ºÀåÀº Àα¸ µ¿Çâ, ÁøÈ­ÇÏ´Â Áø´Ü ¹æ¹ý, ¼ÒºñÀÚ ÇൿÀÇ º¯È­¿Í °ü·ÃµÈ ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÃÖ¼Òħ½ÀÀû ½Ã¼ú, ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç, ¿µ»ó Áø´Ü ¹æ¹ýÀÇ ±â¼úÀû ¹ßÀüÀ¸·Î ÀÎÇØ Á¶±â Áø´Ü°ú ¸ÂÃãÇü °³ÀÔÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÃÖÁ¾ ¿ëµµ Ãø¸é¿¡¼­´Â ºñ´¢±â°ú Ŭ¸®´Ð, Àü¹® º´¿ø, ¿Ü·¡È¯ÀÚ ¼¾ÅÍÀÇ È¯ÀÚ ¼ö°¡ Áõ°¡Çϸ鼭 ƯÈ÷ °í·ÉÈ­ »çȸ¿¡¼­ Á¾ÇÕÀûÀÎ °ËÁø ¹× Ä¡·á ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ ¼±È£µµµµ ÁøÈ­Çϰí ÀÖÀ¸¸ç, ¿ø°ÝÀÇ·á, ¸ÂÃãÇü ÀÇ·á, ÀçÅà °Ë»ç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ëÀÌ È®´ëµÇ¸é¼­ ÀÇ·á ¼­ºñ½º Á¦°ø ¹× ¼Òºñ ¹æ½Ä¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï ½ÃÀåÀÇ ÀÇ·á ÀÎÇÁ¶ó È®ÃæÀº Àü¸³¼± °Ç°­ ¼­ºñ½º¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ Á¢±ÙÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àü¸³¼± °ü·Ã Áúȯ¿¡ ´ëÇÑ ÀǾàǰ ÆÄÀÌÇÁ¶óÀÎÀº źźÇϸç, »õ·Î¿î È£¸£¸ó ¿ä¹ý ¹× º´¿ë ¿ä¹ý¿¡ ÃÊÁ¡À» ¸ÂÃá ¸¹Àº ÀÓ»ó½ÃÇèÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ÀÇ·á ±â¼ú Çõ½Å, ȯÀÚ ÀνÄ, Á¦µµÀû Áö¿øÀÌ ±³Â÷Çϸ鼭 Àü¸³¼± °Ç°­ ½ÃÀåÀÌ Àü ¼¼°è¿¡¼­ Áö¼ÓÀûÀ¸·Î ¼ºÀåÇÒ ¼ö ÀÖ´Â ºñ¿ÁÇÑ È¯°æÀÌ Á¶¼ºµÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Áúȯ À¯Çü(Àü¸³¼±¿° Áúȯ À¯Çü, Àü¸³¼± ºñ´ëÁõ Áúȯ À¯Çü, Àü¸³¼±¾Ï Áúȯ À¯Çü), Ä¡·á(È­Çпä¹ý Ä¡·á, È£¸£¸ó ¿ä¹ý Ä¡·á, ¸é¿ªÄ¡·á Ä¡·á), Åõ¿© °æ·Î(°æ±¸ °æ·Î, ºñ°æ±¸ °æ·Î), À¯Åë ä³Î(º´¿ø ¾à±¹ À¯Åë ä³Î, ¼Ò¸Å ¾à±¹ À¯Åë ä³Î, ¿Â¶óÀÎ ¾à±¹ À¯Åë ä³Î)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÇÕ°è 37 ÁÖ¸ñ)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÔ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <>Áß±¹ <>¸ß½ÃÄÚ <>ij³ª´Ù <>EU <>ÀϺ» <>Àεµ <>±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Prostate Health Market to Reach US$51.2 Billion by 2030

The global market for Prostate Health estimated at US$33.8 Billion in the year 2024, is expected to reach US$51.2 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Prostatitis Disease, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$27.4 Billion by the end of the analysis period. Growth in the Benign Prostatic Hyperplasia Type segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.2 Billion While China is Forecast to Grow at 11.0% CAGR

The Prostate Health market in the U.S. is estimated at US$9.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.6 Billion by the year 2030 trailing a CAGR of 11.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global "Prostate Health" Market - Why Is Proactive Care Becoming a Global Men’s Health Imperative?

Is the Aging Population Raising the Urgency Around Prostate Health?

Prostate health is becoming a central concern in global healthcare systems, largely due to the rapid aging of the male population and increased awareness around urological conditions. Prostate-related disorders such as benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer are increasingly prevalent among men aged 50 and above, creating steady demand for preventive, diagnostic, and therapeutic solutions. Public health campaigns and enhanced screening protocols have led to early detection, contributing to better prognosis and a wider treatment window. Additionally, lifestyle-related risk factors-such as obesity, smoking, and sedentary habits-are exacerbating the incidence of prostate issues, even in younger age groups. The expansion of diagnostic tools like PSA testing, MRI, and transrectal ultrasound is making prostate health monitoring more accessible and precise. Governments and health organizations are integrating prostate care into regular male health checkups, particularly in North America, Europe, and parts of Asia, further boosting awareness and demand for clinical interventions.

Are Innovations in Diagnosis and Treatment Enhancing Clinical Outcomes?

The prostate health market is benefiting significantly from advancements in diagnostic and therapeutic technologies. Minimally invasive surgical techniques, such as laser therapy, TURP (transurethral resection of the prostate), and newer robotic-assisted procedures, are reducing recovery time and improving quality of life for patients. Pharmacological innovation is also playing a key role; newer generations of alpha-blockers, 5-alpha reductase inhibitors, and hormone therapies are offering more targeted symptom management with fewer side effects. Diagnostic imaging is becoming more precise with multiparametric MRI and biomarker-based tests allowing earlier and more accurate differentiation between benign conditions and malignancies. Furthermore, research into immunotherapy and radiopharmaceuticals is showing promise in treating advanced-stage prostate cancer. Digital health tools, such as tele-urology platforms and mobile health apps, are supporting patient compliance, symptom tracking, and virtual consultations. As diagnostics and therapeutics become more integrated, holistic care pathways are emerging, improving clinical workflows and patient outcomes.

Is Male Health Awareness and Consumer Behavior Driving Demand?

Societal shifts in how men approach their health are transforming the prostate health landscape. Traditionally underdiagnosed due to stigma and neglect, prostate conditions are now receiving increased attention thanks to advocacy from celebrities, medical societies, and digital influencers. Younger generations are more proactive about preventive care, participating in regular checkups and genetic screenings. Direct-to-consumer health platforms and home testing kits are giving men more autonomy in managing their health, while pharmacies and primary care clinics offer greater accessibility to prostate-specific services. The growing emphasis on sexual wellness and quality of life is also pushing patients to seek early treatment for conditions like BPH and erectile dysfunction, which are often interlinked with prostate health. Men are becoming more educated on the long-term implications of prostate disease, such as incontinence or cancer, and are therefore more willing to invest in premium diagnostics, second opinions, and ongoing care regimens. These behavioral trends are gradually shifting the market from reactive treatment toward a more preventive, personalized, and patient-centric model.

The Growth in the Prostate Health Market Is Driven by Several Factors…

The growth in the prostate health market is driven by several factors related to demographic trends, evolving diagnostics, and shifting consumer behavior. Technological advancements in minimally invasive procedures, biomarker testing, and imaging modalities are allowing for earlier diagnosis and tailored interventions. From an end-use perspective, the rising patient volumes in urology clinics, specialty hospitals, and outpatient centers-especially in aging economies-are pushing demand for comprehensive screening and treatment services. Consumer preferences are also evolving, with increased acceptance of telehealth, personalized medicine, and at-home testing solutions influencing how care is delivered and consumed. Healthcare infrastructure expansion, particularly in emerging markets, is enabling broader access to prostate health services. Moreover, the pharmaceutical pipeline for prostate-related conditions is robust, with numerous clinical trials focused on novel hormonal therapies and combination regimens. The intersection of medical innovation, patient awareness, and systemic support is creating a fertile environment for the sustained growth of the prostate health market globally.

SCOPE OF STUDY:

The report analyzes the Prostate Health market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type, Prostate Cancer Disease Type); Treatment (Chemotherapy Treatment, Hormone Therapy Treatment, Immunotherapy Treatment); Administration Route (Oral Route, Parenteral Route); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â